英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
dodrans查看　dodrans　在百度字典中的解释百度英翻中〔查看〕
dodrans查看　dodrans　在Google字典中的解释Google英翻中〔查看〕
dodrans查看　dodrans　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA Approves Adbry for Treatment of Moderate-to-Severe Atopic . . .
    The FDA has approved tralokinumab-ldrm (Adbry, LEO Pharma) for the treatment of moderate-to-severe atopic dermatitis (AD) for adults whose disease is not well controlled with topical prescription therapies or when those therapies are not advisable Tralokinumab-ldrm can be used with or without topical corticosteroids Tralokinumab-ldrm is an injection and is the first and only FDA-approved
  • FDA Approves Dupilumab for Treatment of Bullous Pemphigoid
    The FDA approves dupilumab as the first targeted treatment for bullous pemphigoid, offering hope for patients with this debilitating skin condition
  • FDA Approves Tralokinumab-ldrm Autoinjector for Adults With Atopic . . .
    The FDA has approved a new tralokinumab-ldrm (Adbry; LEO Pharma) 300 mg single-dose autoinjector for adult patients with moderate-to-severe atopic dermatitis Tralokinumab-ldrm is currently indicated for moderate-to-severe atopic dermatitis in patients aged 12 years and older 1 According to a news release, the autoinjector will provide another option for adults in addition to the prefilled
  • Daily Medication Pearl: Tralokinumab-ldrm (Adbry) - Pharmacy Times
    Medication Pearl of the Day: Tralokinumab-ldrm (Adbry) Indication: Tralokinumab-ldrm (Adbry) is an interleukin-13 (IL-13) antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
  • Experts: Current Treatment Regimens and the Future for Plaque Psoriasis . . .
    In addition to current treatment regimens, 2 experts discuss how available options can vary between adult and pediatric patients
  • Tralokinumab-ldrm Shows Significant Improvements in Symptoms of Atopic . . .
    Treatment with tralokinumab-ldrm (Adbry; LEO Pharma) produced significant improvements in itch, sleep interference, anxiety, depression, and overall quality of life among patients 12 to 17 years of age with moderate-to-severe atopic dermatitis (AD)
  • Nemolizumab Granted FDA Approval For Adults Living With Prurigo . . .
    Nemolizumab was previously granted breakthrough therapy designation in December 2019, and Galderma’s regulatory filing for priority review of the drug was approved in February 2024 by the FDA This status is granted to medicines that have potential to significantly improve the treatment of rare conditions 2,3 “The US FDA’s rapid approval of Nemluvio in prurigo nodularis is a first step
  • Lebrikizumab Demonstrates Improvements in Skin Clearance, Itch Relief . . .
    Key Takeaways Lebrikizumab showed significant efficacy in improving skin and reducing itch in patients with moderate to severe atopic dermatitis previously treated with dupilumab The ADapt trial reported 57% and 60% of patients achieved EASI-75 at weeks 16 and 24, respectively The safety profile of lebrikizumab was consistent with previous trials, with mild to moderate adverse events
  • Navigating Pediatric Atopic Dermatitis: Insights Into Treatment . . .
    Tralokinumab-ldrm (Adbry; LEO Pharma Inc) and, more recently, lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) are IL-13 inhibitors approved for moderate to severe disease in patients aged 12 and older 9 Refer to Table 1 for dosing, adverse effects (AEs), and clinical pearls
  • Not A Laughing Matter: Emerging Nitrous Oxide Regulatory Oversight
    Nitrous oxide (N 2 O) is an inhaled anesthetic and analgesic used in minor surgical procedures Discovered in 1772, it is commonly known as “laughing gas” and causes minimal respiratory depression and hemodynamic changes when compared to other anesthetics 1





中文字典-英文字典  2005-2009